Study of Low Molecular Weight Heparins

Launched by HERLEV HOSPITAL · Aug 29, 2023

Keywords

ClinConnect Summary

The DANHEP clinical trial is studying two types of blood-thinning medications called low molecular weight heparins, specifically dalteparin and tinzaparin. These medications are commonly used to prevent and treat blood clots in patients, especially those with cancer, who are in the hospital for medical reasons, or who have had surgery. Although both medications are thought to work equally well and be safe, this study aims to gather more evidence to see if they are truly comparable in terms of how safe and effective they are for patients who need them.

To participate in this study, patients should be at least 18 years old and have a valid reason to be prescribed one of these blood thinners. However, people who are unable to understand the study materials, choose not to participate after being informed, or have specific medical reasons against using these medications will not be eligible. If you join the study, you can expect to help researchers learn more about these medications, which could improve treatment options for future patients. The trial is currently recruiting participants, and it welcomes individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with indication for low molecular weight heparin
• Exclusion Criteria:
• • Patients under the age of 18
• • Patients who are incapable of understanding the written material received
• • Patients who after being informed in writing chooses not to participate
• • Patients with contraindications for low molecular weight heparins as described in the SmPC